In the pivotal study KEYNOTE-012 conducted in 2014, initial findings were obtained from a cohort of patients diagnosed with advanced GC, all of whom had previously undergone treatment with an anti-PD-1 or anti-PD-L1 monoclonal antibody. Here, CD274 is linked to gastric cancer.